Clone:
REAL225
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC
Alternative names:
BDCA-2

Extended validation for CD303 (BDCA-2) Antibody, anti-human,
REAlease
®

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REAL225
AC144++
201A++
V24-785++
REA693++
Cells were incubated with an excess of purified unconjugated CD303 (BDCA-2) (REAL225) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Specifications for CD303 (BDCA-2) Antibody, anti-human,
REAlease
®

Overview

Clone REAL225 is an antibody fragment derived from the full CD303 (BDCA-2) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
CD303 (BDCA-2) antibodies have been used, for example, to identify, characterize, and enumerate plasmacytoid dendritic cells in whole blood of healthy and HIV-infected individuals, and for analyzing the role of DC-SIGN in HIV infection and transmission. Furthermore, CD303 (BDCA-2) antibodies were used to identify and enumerate plasmacytoid dendritic cells in blood and bone marrow samples before and after hematopoietic stem cell mobilization or transplantation. CD303 (BDCA-2) antibodies were also used for immunohistochemical staining, for example to identify plasmacytoid dendritic cells in tissue sections from patients with different inflammatory skin diseases.
Clone REAL225 recognizes the CD303 (BDCA-2) antigen which is expressed on human plasmacytoid dendritic cells in blood, lymphoid (e.g. tonsils and bone marrow), and non-lymphoid tissue. Specific expression allows direct identification of plasmacytoid dendritic cells using just one marker. CD303 (BDCA-2)
+
plasmacytoid dendritic cells in blood and bone marrow are CD11c
, CD123
high
, CD4
+
, Lin
, CD45RA
+
, CD304 (BDCA-4/Neuropilin-1)
+
, CD141 (BDCA-3)
low
, CD1c (BDCA-1)
, CD14
, and CD2
. They express neither myeloid lineage markers (CD13, CD33) nor Fc receptors (CD32, CD64, FcRI). CD303 (BDCA-2) is strongly expressed on freshly isolated plasmacytoid dendritic cells but down-regulated within 48 hours of culturing. Unlike CD304 (BDCA-4/Neuropilin-1), CD303 (BDCA-2) is not detectable on ex vivo generated monocyte-derived or hematopoietic precursor cell-derived CD1a
+
dendritic cells.
The CD303 (BDCA-2) antigen is a type II transmembrane C-type lectin. Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells. Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I interferon production, which is induced in plasmacytoid dendritic cells by, for example, the influenza virus.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

BDCA-2

Detailed product information

Technical specifications

CloneREAL225
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD303 (BDCA-2)
Alternative names of antigenBDCA-2
Distribution of antigendendritic cells, macrophages, monocytes, neutrophils, bone marrow
RRIDAB_2784119, AB_2751918

Related products for
CD303 (BDCA-2) Antibody, anti-human,
REAlease
®

3 products available